<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598310</url>
  </required_header>
  <id_info>
    <org_study_id>OMC BC-04</org_study_id>
    <secondary_id>OMC BC-04</secondary_id>
    <nct_id>NCT02598310</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab
      for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>Up to 12 weeks after the protocol therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Five years after the last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 6 weeks after the protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>Up to 12 weeks after the protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast-conserving surgery rate</measure>
    <time_frame>Up to 6 weeks after the protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 6 weeks after the protocol therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Estrogen Receptor Negative Neoplasm</condition>
  <condition>HER-2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel plus trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel 260mg/m2 q3w</description>
    <arm_group_label>nab-paclitaxel plus trastuzumab</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>trastuzumab 6 mg/kg (8 mg/kg as the loading dose)</description>
    <arm_group_label>nab-paclitaxel plus trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed invasive breast cancer

          2. Tumor size of 3cm or less and N0

          3. Hormone receptors have been identified as negative

          4. HER2 positive confirmed by IHC 3+ or FISH+

          5. LVEF &gt; 50% by echocardiogram or MUGA

          6. Adequate EKG

          7. No prior treatment for breast cancer

          8. PS 0-1

          9. Required baseline laboratory data WBC &gt; 4,000/mm3 and Neut &gt; 2,000/mm3 PLT &gt;
             100,000/mm3 Hb &gt; 9.0g/dl AST and ALT &lt; ULNx2.5 T-Bil &lt; 1.5mg/dl Serum creatinin &lt;
             1.5mg/dl

         10. Written informed consent

        Exclusion Criteria:

          1. With history of hypersensitivity reaction for important drug in this study

          2. With history of invasive breast cancer

          3. Bilateral invasive breast cancer

          4. Patients with medical conditions that renders them intolerant to primary chemotherapy
             and related treatment, including infection, diarrhea, intestinal paralysis, severe
             Diabetes Mellitus

          5. Positive for HBs antigen or HCV antibody

          6. With history of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction, poorly controlled hypertension

          7. With severe edema

          8. With severe peripheral neuropathy

          9. With severe psychiatric disorder

         10. Pregnant or nursing women

         11. The case that is judged to be unsuitable for this study by physician
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuhiko Iwamoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Satoru Tanaka, MD, PhD</last_name>
    <phone>+81-72-683-1221</phone>
    <email>sur112@osaka-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimura Kosei, MD, PhD</last_name>
    <phone>+81-72-683-1221</phone>
    <email>sur121@osaka-med.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Osaka Medical College</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>5698686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoru Tanaka, MD, PhD</last_name>
      <email>sur112@osaka-med.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Mitsuhiko Iwamoto, MD, PhD</last_name>
      <email>sur067@osaka-med.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Kosei Kimura, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiroya Fujioka, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka Medical College</investigator_affiliation>
    <investigator_full_name>Satoru Tanaka</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

